TELBUVIDINE MONOTHERAPY IN THE TREATMENT OF HBEAG POSITIVE CHRONIC HEPATITIS B INFECTION WITH NORMAL BASELINE ALT LEVELS | [Journal of Postgraduate Medical Institute • 2013]

Author(s):

1. Muhammad Tariq Mehr: Department of Medicine, Khyber Teaching Hospital, Peshawar, Pakistan

2. Humera Khan: Department of Medicine, Rehman Medical Institute,Peshawar ,Pakistan

3. Noor Ul Iman: Department of Medicine, Khyber Teaching Hospital, Peshawar, Pakistan

Abstract:

To study the effect of Telbuvidine (LDT) monotherapy in the treatment of HBeAg positive Chronic Hepatitis B infection (CHB) with normal ALT levels. Methodology: Ninety HBe antigen (HBeAg) positive CHB infection patients were enrolled & followed between June 2008 and June 2011. All of them had ALT levels less than twice the upper normal limit (Mean 36.9 SD 19.9). All patients were HBeAg positive, had serum DNA level ?104 copies/ml and never had previously received anti HBV treatment. All patients were given LDT 600mg daily as initial antiviral treatment for two years. Results: Out of 83 patients who continued the treatment as per protocol, 59 were males and 24 were females between ages of 21 and 50 years. Baseline HBV DNA levels were 7.82x107 copies/ml (Range 4.8x104-8.3x109copies/ml). By the end of first year (52 weeks) the mean decrease in serum HBV DNA levels was 7.88 log10 copies/ml and the proportion of patients having undetectable HBV DNA levels was 73%. At the end of second year of therapy (96 weeks) the percentage of undetectable HBV DNA levels increased to 86%.At the end of 1st (52weeks) and 2nd (96weeks) HBeAg seroconversion rates were 62 % and 86% while HBsAg seroconversion was 8% and 13% respectively. Conclusion: LDT is a reasonable cost effective therapy for HBeAg reactive CHB patients with normal baseline ALT levels resulting in a significant serological and virological response and was well tolerated in our population of Khyber Pukhtunkhwa.

Page(s): 38-41

DOI: DOI not available

Published: Journal: Journal of Postgraduate Medical Institute, Volume: 27, Issue: 1, Year: 2013

Keywords:

Hepatitis B virus , Telbuvidine , HBeAg

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views